• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Tofacitinib in interstitial lung disease complicated with anti-MDA5 antibody-positive dermatomyositis: A literature review.

作者信息

Takanashi Satoshi, Kaneko Yuko, Takeuchi Tsutomu

机构信息

Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.

出版信息

Mod Rheumatol. 2022 Jan 5;32(1):231-237. doi: 10.1080/14397595.2021.1906505.

DOI:10.1080/14397595.2021.1906505
PMID:33769925
Abstract
摘要

相似文献

1
Tofacitinib in interstitial lung disease complicated with anti-MDA5 antibody-positive dermatomyositis: A literature review.托法替布治疗合并抗MDA5抗体阳性皮肌炎的间质性肺疾病：文献综述
Mod Rheumatol. 2022 Jan 5;32(1):231-237. doi: 10.1080/14397595.2021.1906505.
2
Efficacy of tofacitinib for slowly progressive interstitial lung disease in a patient with anti-MDA5 antibody-positive dermatomyositis.托法替布治疗抗MDA5抗体阳性皮肌炎患者缓慢进展性间质性肺病的疗效
Clin Immunol. 2020 Jun;215:108451. doi: 10.1016/j.clim.2020.108451. Epub 2020 Apr 29.
3
Treatment of MDA5-positive dermatomyositis complicated by gangrenous cholecystitis with tofacitinib.托法替布治疗 MDA5 阳性皮肌炎合并坏疽性胆囊炎
Eur J Med Res. 2022 May 15;27(1):68. doi: 10.1186/s40001-022-00693-0.
4
Efficiency of tofacitinib in refractory interstitial lung disease among anti-MDA5 positive juvenile dermatomyositis patients.托法替布在抗MDA5阳性幼年皮肌炎患者难治性间质性肺疾病中的疗效
Ann Rheum Dis. 2023 Nov;82(11):1499-1501. doi: 10.1136/ard-2023-223919. Epub 2023 Jun 6.
5
Successful Treatment for Refractory Interstitial Lung Disease and Pneumomediastinum With Multidisciplinary Therapy Including Tofacitinib in a Patient With Anti-MDA5 Antibody-Positive Dermatomyositis.托法替布联合多学科治疗成功治愈抗MDA5抗体阳性皮肌炎患者的难治性间质性肺病和气纵膈
J Clin Rheumatol. 2021 Dec 1;27(8S):S574-S577. doi: 10.1097/RHU.0000000000000984.
6
A Case of Refractory Interstitial Lung Disease in Anti-MDA5-Positive Dermatomyositis That Improved After Switching to Tofacitinib.1例抗MDA5阳性皮肌炎患者难治性间质性肺疾病在换用托法替布后病情改善
J Clin Rheumatol. 2021 Dec 1;27(8S):S661-S662. doi: 10.1097/RHU.0000000000001645.
7
Anti-MDA5 Antibody-positive Clinically Amyopathic Dermatomyositis with Rapidly Progressing Interstitial Lung Disease Successfully Treated by Initiation of Combined Immunosuppressive Therapy Plus Plasma Exchange and Subsequently Switching Tacrolimus to Tofacitinib.抗MDA5抗体阳性的临床无肌病性皮肌炎合并快速进展性间质性肺病，通过启动联合免疫抑制治疗加血浆置换，随后将他克莫司换为托法替布成功治疗。
Intern Med. 2024 Sep 15;63(18):2571-2578. doi: 10.2169/internalmedicine.2915-23. Epub 2024 Feb 12.
8
Fatal outcome of anti-MDA5 juvenile dermatomyositis in a paediatric COVID-19 patient: a case report.一名儿童COVID-19患者中抗MDA5型幼年皮肌炎的致命结局：病例报告
Mod Rheumatol Case Rep. 2021 Jan;5(1):101-107. doi: 10.1080/24725625.2020.1832755. Epub 2020 Oct 20.
9
Anti-MDA5 antibody-associated clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease.抗MDA5抗体相关的临床无肌病性皮肌炎伴快速进展性间质性肺病。
Joint Bone Spine. 2022 Nov;89(6):105456. doi: 10.1016/j.jbspin.2022.105456. Epub 2022 Sep 13.
10
Tofacitinib in Amyopathic Dermatomyositis-Associated Interstitial Lung Disease.托法替布治疗无肌病性皮肌炎相关间质性肺疾病
N Engl J Med. 2019 Jul 18;381(3):291-293. doi: 10.1056/NEJMc1900045.

引用本文的文献

1
Effectiveness and safety of tofacitinib calcineurin inhibitor in interstitial lung disease secondary to anti-MDA5-positive dermatomyositis: a multicentre cohort study.托法替布联合钙调神经磷酸酶抑制剂治疗抗MDA5阳性皮肌炎继发间质性肺病的有效性和安全性：一项多中心队列研究
Eur Respir J. 2025 May 22;65(5). doi: 10.1183/13993003.01488-2024. Print 2025 May.
2
Past, Present, and Future in Dermatomyositis Therapeutics.皮肌炎治疗的过去、现在与未来
Curr Treatm Opt Rheumatol. 2022 Dec;8(4):71-90. doi: 10.1007/s40674-022-00193-6. Epub 2022 Jul 26.
3
Baricitinib for anti-melanoma differentiation-associated protein 5 antibody-positive dermatomyositis-associated interstitial lung disease: a case series and literature review on Janus kinase inhibitors for the disease.
巴利昔替尼治疗抗黑色素瘤分化相关蛋白 5 抗体阳性的皮肌炎相关间质性肺病：关于 Janus 激酶抑制剂治疗该病的病例系列及文献复习。
Rheumatol Int. 2024 May;44(5):961-971. doi: 10.1007/s00296-024-05551-2. Epub 2024 Mar 8.
4
Upadacitinib therapy in refractory inflammatory myositis: a case series of 10 patients.难治性炎性肌病的乌帕替尼治疗：10 例病例系列。
RMD Open. 2024 Jan 18;10(1):e003837. doi: 10.1136/rmdopen-2023-003837.
5
Ground-glass opacity score predicts the prognosis of anti-MDA5 positive dermatomyositis: a single-centre cohort study.磨玻璃影评分预测抗 MDA5 阳性皮肌炎的预后：一项单中心队列研究。
Orphanet J Rare Dis. 2023 Jul 21;18(1):208. doi: 10.1186/s13023-023-02827-x.
6
Anti-MDA5-positive dermatomyositis and remission in a single referral centre population.单中心就诊人群中抗 MDA5 阳性皮肌炎及缓解情况
Clin Exp Rheumatol. 2023 Mar;41(2):309-315. doi: 10.55563/clinexprheumatol/g4l70r. Epub 2023 Feb 15.
7
Mortality Risk Stratification Using Cluster Analysis in Patients With Myositis-Associated Interstitial Lung Disease Receiving Initial Triple-Combination Therapy.使用聚类分析对接受初始三联联合治疗的肌炎相关间质性肺病患者进行死亡风险分层
Front Med (Lausanne). 2022 May 9;9:883699. doi: 10.3389/fmed.2022.883699. eCollection 2022.